Cited 2 times in
Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 권혁문 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 신동호 | - |
dc.contributor.author | 이병권 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 안철민 | - |
dc.date.accessioned | 2020-02-26T06:45:41Z | - |
dc.date.available | 2020-02-26T06:45:41Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175277 | - |
dc.description.abstract | BACKGROUND: Evaluate the safety and efficacy of guideline-recommended risk score-directed dual antiplatelet therapy (GD-DAPT) based on THE PRECISE-DAPT score after 2nd-generation drug-eluting stent (DES) implantation.Methods and Results:We analyzed 5,131 patients pooled from 4 clinical trials. Patients were divided into 3 groups according to current recommendations on the duration of DAPT and their actual DAPT duration: GD-DAPT (n=2,183), shorter DAPT (n=1,540), longer DAPT (n=1,408). The primary endpoint was the rate of net adverse clinical events (NACE) during the first 12 months. The secondary endpoints were ischemic or bleeding events. Overall, GD-DAPT did not affect NACE (1.2% vs. 1.2% for shorter DAPT and 1.7% for longer DAPT) or bleeding events (0.6% vs. 0.5% and 0.9%), and there were fewer ischemic events (2.8% vs. 4.4% and 4.0%, P=0.03) than with shorter DAPT. Especially in acute coronary syndrome (ACS) patients, GD-DAPT had fewer NACE (1.5% vs. 1.4% and 4.2%; P=0.006) and bleeding events (0.8% vs. 0.5% and 2.8%; P=0.001) than longer DAPT as well as fewer ischemic events (2.8% vs. 4.4% and 4.7%; P=0.03) than shorter DAPT. CONCLUSIONS: GD-DAPT did not affect NACE or bleeding events and reduced the number of ischemic events at 12 months compared with shorter DAPT. For ACS, GD-DAPT was associated with favorable outcomes compared with non-GD-DAPT. Therefore, GD-DAPT may optimize efficacy and safety. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English, Japanese | - |
dc.publisher | Japanese Circulation Society | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy and Safety of Guideline-Recommended Risk Score-Directed Dual Antiplatelet Therapy After 2nd-Generation Drug-Eluting Stents | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji-Yong Jang | - |
dc.contributor.googleauthor | Byoung-Kwon Lee | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Dong-Ho Shin | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Kyung Woo Park | - |
dc.contributor.googleauthor | Hyeon-Cheol Gwon | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.contributor.googleauthor | Hyuck Moon Kwon | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.1253/circj.CJ-19-0667 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00260 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A05648 | - |
dc.contributor.localId | A02793 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J00534 | - |
dc.identifier.eissn | 1347-4820 | - |
dc.identifier.pmid | 31839621 | - |
dc.subject.keyword | Drug-eluting stent | - |
dc.subject.keyword | Dual antiplatelet duration | - |
dc.subject.keyword | PRECISE-DAPT risk score | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 권혁문 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 신동호 | - |
dc.contributor.affiliatedAuthor | 이병권 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 84 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 161 | - |
dc.citation.endPage | 168 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, Vol.84(2) : 161-168, 2020 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.